ERBB2 and gastric cancer: To further explore the role of SMADs in gastric cancer, clinicopathological features such as pathological stages (Table 1), differentiation (Table 2), gender (Table 3), treatment strategies (Table 4) and Her2 status (Table 5) were evaluated.